Experimental MS Oral Antibiotic Combination Therapy Showing Promise in Phase 2a Study, RedHill Biopharma Reports

Experimental MS Oral Antibiotic Combination Therapy Showing Promise in Phase 2a Study, RedHill Biopharma Reports

RedHill Biopharma, Ltd. recently announced promising interim results from its ongoing CEASE-MS Phase 2a clinical trial evaluating the safety and efficacy of a fixed dose of RHB-104 as an add-on therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS).

RHB-104 consists of an oral capsule formulation of an antibiotic combination therapy — 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine — with strong intracellular, anti-mycobacterial, and anti-inflammatory properties. Originally developed for the treatment of Crohn’s disease, this drug is now being pursued as a complementary therapy for RRMS due to its potential anti-inflammatory and neuroprotective activity.

The CEASE-MS study, “Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis,” is a proof-of-concept clinical trial also exploring the efficacy of RHB-104 as an adjuvant therapy to interferon beta-1a in 18 patients with RRMS. The recently announced results refer to safety and clinical evidence after 24 weeks of treatment.

Annualized relapse rate (ARR) at 24 weeks was 0.288 in the modified intent-to-treat (mITT) population (all study participants), and 0.0 in the per-protocol (PP) population (the cohort analyzed). These results compare favorably with previously reported data of interferon beta-1a therapies Avonex and Rebif, RedHill announced in a company press release.

Also at 24 weeks, 88 percent of the mITT patient population and 100 percent of the PP group were relapse free, compared with Rebif (75%) and with Avonex (63%) as standalone therapies. Moreover, no patients in the CEASE-MS study relapsed after week eight of treatment, and no increase in total Expanded Disability Status Scale (EDSS), a measure of disability in MS, was observed in any patient during the treatment period.

Results also indicated a reduction in MRI T2 lesion volume, a definition of burden of disease and indicator of response and progression in RRMS, at 24 weeks of treatment with RHB-104 as compared to baseline. Such results again compared favorably to previous data for Avonex and Rebif treatment. Importantly, RHB-104 was found to be safe and well-tolerated, and no drug-related serious side-effects were observed.

“We are very pleased with the interim results from the ongoing CEASE-MS Phase IIa proof-of-concept study with RHB-104 for relapsing-remitting multiple sclerosis (RRMS). The initial findings from the study, including safety, clinical and MRI, support the therapeutic potential of RHB-104 as add-on therapy in RRMS,” said Dr. Ira Kalfus, MD, medical director of RedHill and for the CEASE-MS study. “Although designed as an exploratory proof-of-concept study in a very small patient population and not powered for efficacy, the study interim results demonstrate positive safety data and clinical signals, supporting additional studies to better investigate the therapeutic potential of RHB-104 in RRMS.”

Dr. Radi Shahien, MD, principal investigator of the CEASE-MS study, added: “RRMS is a devastating disease with no known cure, limited treatment options and unknown cause, hence the importance of the development of RHB-104, an intracellularly acting, anti-mycobacterial, anti-inflammatory and orally administered drug candidate. CEASE-MS is … intended to investigate the groundbreaking hypothesis that a bacterial induced dysregulated immune system plays a critical role in the pathogenesis of MS. RedHill’s CEASE-MS study with RHB-104 is the first clinical study to evaluate the therapeutic potential of a triple antibiotic combination therapy, and specifically these intracellularly acting antibiotics, as add-on therapy in RRMS. The initial analysis of the study’s interim results provides encouraging clinical signals as well as important and reassuring safety data. In particular, the reduction of total T2 lesion burden over baseline, a key MS disease burden measurement, as well as relapse-free and stable EDSS data, are positive and meaningful signals, particularly given the small patient population in the study and the early time point of the data generated to date. I find the interim results very promising and am encouraged by the potential efficacy of RHB-104 in treating MS. I look forward to the completion of the study, further analyses and presentation of the final data at the appropriate international medical and academic forums.”

RedHill Biopharma, Ltd. is an Israeli company focused on the development and commercialization of oral-administered small-molecule medicines for inflammatory and gastrointestinal diseases.

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • Sensory processing, fatigue, and cognition assessment in MS clinical care
  • sleep
  • Depression, fatigue, decline in cognitive function in women with MS
  • MS and parasitic worms
Average Rating
0 out of 5 stars. 0 votes.
My Rating:


  1. Michael howells says:

    Please help me i am loosing mobility on my right hand side of my body and its moving over to my left shoulder i have a full lesion on my left brain and another one on the front right hand side.

    • john Smith says:

      Stewed blueberries without water added seem to help me kill poisons in the body. High Alkaline low acidity diet, wet cell battery from iodinesource.com owned by phil thomas and based on the edgar cayce readings. Salad for lunch of just green vegetables without dressing sprinkled with gelatin.

    • Sean Reynolds says:

      You can start on the Wheldon protocol right away without waiting for this drug, which is just a hopeless rehash of other drugs that are already available, trying to cash in by creating a new patent on existing drugs. These are not even the best antibiotics to use.

      The Wheldon Protocol just requires you to throw roxithromycin, doxycycline and metronidazole at the likely causative agent which is chlamydia pneumoniae. And then you have a choice of either a fourth antibiotic, penicillin, or the amino acid n-acetylcysteine of which the latter is far preferable, because it’s safer, cheaper, and better for you.

      Don’t waste any time, get on to it.

    • Stacey Snow says:

      This study appears to be modeled after Dr.David Wheldon from London who developed this trio for his wife who had MS .
      Based on the Chlamydia pneumoniae, not the Chlamydia STD.
      It’s a respiratory infection.
      It was seen in the CSF of 16 of 16 MS patients.
      His wife is doing well and living MS free for over 10 years

  2. This is very gratifying affirmation of the triple antibiotic treatment that I’ve been on for two years. I am following the Combined Antibiotic Protocol as laid out by Dr David Wheldon in his treatment for MS. I have never taken any other MS drugs and my condition is 95% resolved. I probably have another 2 years on the antibiotics to make sure the cryptic phase are totally exterminated. The initial research was done by Dr Chuck Stratton at Vanderbilt.

  3. Shasha says:

    If antibiotics help the MS person may also have Lyme. Antibiotics hurt my gut lining/hurt my mitochondria and lowered my immune system. Mitochondria are the engines of the cell…burn food/oxygen and make ATP energy. Hurting them may make MS worse. Herbals are safer to kill Lyme.

    • tyler says:

      Autoimmune system is regulated by interleukin cytokines. There is heavy correlation between interleukin-17, Mycobacterium Avium complex bacteria, and autoimmune diseases of all type. Doesn’t mean it will eventually pan out but that’s the theory. Inflammation from this bacterial infection causes a flood of the cytokines which control the targeting of the immune system… And from there s#it happens.

      • Shasha says:

        Hi, Yes…I agree. I currently have Lyme, but MS started 30 years ago when I had two babies in a row that drained vitamins/good oils out of me and I didn’t know I was Celiac which also lowers nutrients absorbed. Gluten made antibodies to my thyroid and then my MS started due to low oxygen in my brain. Trying to kill Lyme/coinfections is hard since it mitochondria may get hurt. They said mitochondria maybe ancient bacteria that are helping the cells. Any swelling/inflammation in the brain cuts off oxygen. Fixing the Celiac helps the immune system work right. LDN helps block hidden gluten. To me killing Lyme and keeping the good bacteria in the body going strong is hard. Herbals help, but a person needs to rebuild the cells more than hurt the cells with medicine.

      • Tony Milici says:

        If MS patents respond to MAP antibiotic treatment, it is quite clear to me that MAP is involved. Enough of saying that is a theory. All is doing is giving an excuse to dairy and infant formula company not to test for MAP in the milk!!

    • Jo says:

      Hi, you are right. However it is worth to remember, that chlamydia pneumoniae cannot produce ATP, hence it uses our mitochondias’ ATP and consumes our energy

  4. I am the wife of the Dr David Wheldon mentioned above by Irene MacDonald. I started his treatment for my secondary progressive MS in 2003 and I took it all in all for four years. It is now 2016 and I have not had a single MS episode in all this time. I do still have a few MS relics: for instance though I can walk unaided, I can’t run. The best thing for me though, is that I have totally recovered the use of my right arm, which had become virtually paralysed, so I am now able to work again as a fine-artist.

    I did not have Lyme disease but I tested positive for chlamydia pneumonia.

    I think Redhill should be applauded for this work because if their combination off abx works as well for the people in the trial as my very similar combination did for me, MS might soon loose its label of being a disease for which there is no known cure.

    • Sabinchen says:

      Hello..can you please contact me via facebook. I have a couple questions. My name is Sabinchen Vogt.
      Thank you very much2

    • Sandra Bell says:

      Dear Sarah
      My lovely wife Sandra has MS and we would like to be given the chance to follow the same course of
      Treatment that your husband gave you.
      How do we go about it please
      Yours with kind regard. John and Sandra Bell

    • Jeanette Lapsker says:

      We have a family member recently diagnosed with MS. How can we get more information on your treatment? We’re interested in finding out if it’s an option for us.

    • Stacey Snow says:

      I want to start the antibiotic protocol. I’m so glad to hear that you are doing well and enjoy your work with your wonderful husband.
      Why is this happening? Why has nothing been happening with the antibiotic?

  5. beniaiche ammar says:

    i have a serieus form of ms for that i have takene a combinaition of antibiotics still i feel better , welhdon s protocl

  6. Hayth says:

    I heard a lot of people with MS who had positive results with
    diet and natural food.
    Does anybody know a doctor in London who cures patients with only diet and natural food?
    It is very urgent.

    Please let me know.

  7. Emilyn Robinson-Hill says:

    I have Primary Progressive MS. Is it worth me trying the David Wheldon protocol. I am a 56 year old artist from the Slade with 3 grown up children. I am very frustrated with the situation & I eat totally naturally.

  8. Julie says:

    My husband has ms for over ppms for over 20 years and is niw in wheelchair and recently a feeding tube.
    Where and how can he try
    Dr Weldon protocol?
    Thank you.

  9. Jo says:

    Hi, you are right. However it is worth to remember, that chlamydia pneumoniae cannot produce ATP, hence it uses our mitochondias’ ATP and consumes our energy

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This